3 research outputs found
The COMPASS Experiment at CERN
The COMPASS experiment makes use of the CERN SPS high-intensitymuon and
hadron beams for the investigation of the nucleon spin structure and the
spectroscopy of hadrons. One or more outgoing particles are detected in
coincidence with the incoming muon or hadron. A large polarized target inside a
superconducting solenoid is used for the measurements with the muon beam.
Outgoing particles are detected by a two-stage, large angle and large momentum
range spectrometer. The setup is built using several types of tracking
detectors, according to the expected incident rate, required space resolution
and the solid angle to be covered. Particle identification is achieved using a
RICH counter and both hadron and electromagnetic calorimeters. The setup has
been successfully operated from 2002 onwards using a muon beam. Data with a
hadron beam were also collected in 2004. This article describes the main
features and performances of the spectrometer in 2004; a short summary of the
2006 upgrade is also given.Comment: 84 papes, 74 figure
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019